Zobrazeno 1 - 6
of 6
pro vyhledávání: '"карфилзомиб"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 1, Pp 15-25 (2023)
Multiple myeloma (MM) accounts for 1 % of all cancers and about 10 % of all hemoblastoses. The use of innovative technologies with the inclusion of targeted drugs leads to a significant improvement in the quality of pharmacotherapy and the achievemen
Externí odkaz:
https://doaj.org/article/84887573e1e043e4b7fa05d5a39873dd
Autor:
Геров, В., Герова, Д.
Publikováno v:
General Medicine / Obsta Medicina; 2024, Vol. 26 Issue 6, p29-37, 9p
Autor:
Zherebtsova VA; Botkin City Clinical Hospital., Vorobyev VI; Botkin City Clinical Hospital., Gemdzhian EG; National Research Center for Hematology., Ulyanova MA; Botkin City Clinical Hospital., Chernikov MV; Research Institute of Health Organization and Medical Management., Ivanova VL; Botkin City Clinical Hospital., Vinogradova OY; Botkin City Clinical Hospital., Ptushkin VV; Botkin City Clinical Hospital.
Publikováno v:
Terapevticheskii arkhiv [Ter Arkh] 2021 Jul 23; Vol. 93 (7), pp. 785-792. Date of Electronic Publication: 2021 Jul 23.
Autor:
Vera A. Zherebtsova, Vladimir I. Vorobyev, Eduard G. Gemdzhian, Margarita A. Ulyanova, Mikhail V. Chernikov, Valentina L. Ivanova, Olga Yu. Vinogradova, Vadim V. Ptushkin
Publikováno v:
Терапевтический архив, Vol 93, Iss 7, Pp 785-792 (2021)
Carfilzomib, lenalidomide, and dexamethasone (KRd) have been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) based on ASPIRE clinical trial.Analysis of efficacy and safety of KRd in routine clinical practice.The prospect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aaec9703bebb725941b4480f07589f7
https://pubmed.ncbi.nlm.nih.gov/36286729
https://pubmed.ncbi.nlm.nih.gov/36286729
Publikováno v:
Клиническая онкогематология. Фундаментальные исследования и клиническая практика.
Заболевания системы крови включают широкую группу злокачественных опухолей кроветворной и лимфоидной тканей, в основе патогенеза кото
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2806::42831d0bc7d943b880384655c1f8dcb5
http://cyberleninka.ru/article/n/molekulyarno-geneticheskie-narusheniya-v-patogeneze-opuholey-sistemy-krovi-i-sootvetstvuyuschie-im-izmeneniya-signalnyh-sistem-kletki
http://cyberleninka.ru/article/n/molekulyarno-geneticheskie-narusheniya-v-patogeneze-opuholey-sistemy-krovi-i-sootvetstvuyuschie-im-izmeneniya-signalnyh-sistem-kletki